A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Clinical trial NCT07491172 · RECRUITING

Trial details

NCT number: NCT07491172
Sponsor: CRISPR Therapeutics AG
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Cardiovascular Metabolic Disease Dyslipidemias Lipid Disorder Hypertriglyceridemia Heterozygous Familial Hypercholesterolemia (HeFH)Homozygous Familial Hypercholesterolemia (HoFH)Severe Hypertriglyceridemia (sHTG)Mixed Hyperlipemia Hypercholesterolaemia

Start date: 2024-06-21
Primary completion: 2027-06-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.